TY - JOUR
T1 - Immunological aspects of approved MS therapeutics
AU - Rommer, Paulus S.
AU - Milo, Ron
AU - Han, May H.
AU - Satyanarayan, Sammita
AU - Sellner, Johann
AU - Hauer, Larissa
AU - Illes, Zsolt
AU - Warnke, Clemens
AU - Laurent, Sarah
AU - Weber, Martin S.
AU - Zhang, Yinan
AU - Stuve, Olaf
N1 - Publisher Copyright:
© 2019 Rommer, Milo, Han, Satyanarayan, Sellner, Hauer, Illes, Warnke, Laurent, Weber, Zhang and Stuve.
PY - 2019
Y1 - 2019
N2 - Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the course of the disease. Over the past two decades, the treatment landscape has changed tremendously. Currently, more than a dozen drugs representing 1 substances with different mechanisms of action have been approved (interferon beta preparations, glatiramer acetate, fingolimod, siponimod, mitoxantrone, teriflunomide, dimethyl fumarate, cladribine, alemtuzumab, ocrelizumab, and natalizumab). Ocrelizumab was the first medication to be approved for primary progressive MS. The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS. Each agent's clinical development and potential side effects are discussed.
AB - Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-remitting MS to modulate the course of the disease. Over the past two decades, the treatment landscape has changed tremendously. Currently, more than a dozen drugs representing 1 substances with different mechanisms of action have been approved (interferon beta preparations, glatiramer acetate, fingolimod, siponimod, mitoxantrone, teriflunomide, dimethyl fumarate, cladribine, alemtuzumab, ocrelizumab, and natalizumab). Ocrelizumab was the first medication to be approved for primary progressive MS. The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS. Each agent's clinical development and potential side effects are discussed.
KW - Immunomodulation
KW - Immunosuppression
KW - Immunotherapeutics
KW - Monoclonal antibodies
KW - Multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=85069437101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069437101&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2019.01564
DO - 10.3389/fimmu.2019.01564
M3 - Review article
C2 - 31354720
AN - SCOPUS:85069437101
SN - 1664-3224
VL - 10
JO - Frontiers in immunology
JF - Frontiers in immunology
IS - JULY
M1 - 1564
ER -